Limerick site of Eli Lilly launched with a billion euros investment

Eli Lilly, the global pharmaceutical giant, has recently announced the opening of its new billion euro manufacturing site in Ireland’s Limerick city. The facility, which spans 240,000 square feet, is expected to serve as a hub for the production of a range of critical medicines, including oncology and diabetes treatments. The launch of this site marks a significant milestone for the company, and reinforces Ireland’s position as a top location for pharmaceutical innovation and manufacturing. Let’s explore what this announcement means for Eli Lilly, and the industry as a whole.


The American pharmaceutical company, Eli Lilly, has launched its new Biopharmaceutical Campus in Raheen, Limerick, which is expected to draw a €1 billion investment. This state-of-the-art manufacturing site will be fully integrated with digital technology to ensure product and data quality. The facility is anticipated to create over 300 highly skilled jobs with the potential to grow further. The project is estimated to take two and a half years with manufacturing expected to begin in 2025. The Limerick site will produce a range of groundbreaking medicines for diseases such as cancer, auto-immune diseases, and Alzheimer’s. Eli Lilly already has a footprint in Ireland, with 10% of its workforce employed at its Kinsale and Little Island, Cork facilities. The launch was celebrated by Simon Coveney, the Minister for Enterprise, Trade and Employment, who thanked Eli Lilly CEO David Ricks for investing in Ireland.


In conclusion, the launch of Eli Lilly’s billion euro site in Limerick marks a significant milestone for the company’s investment in Ireland and its commitment to innovation and excellence in the pharmaceutical industry. With state-of-the-art facilities and a highly skilled workforce, this site is poised to make a significant contribution to the local economy and improve the lives of patients around the world. As Eli Lilly continues on this path of growth and development, we can be sure that the future holds great promise for the company and its unwavering dedication to advancing healthcare.